医薬品製剤の世界市場レポート 2025年

医薬品製剤の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.3％で2兆9,486億4,000万米ドルに成長します。予測期間の成長は、3Dプリンティングの進歩、小児用製剤への注力、生物学的ドラッグデリバリーシステム、製剤におけるグリーンケミストリー、人工知能（AI）の統合などに起因すると考えられます。予測期間の主な動向には、バイオ医薬品と生物製剤の優位性、先進ドラッグデリバリーシステム、個別化医療と個別化製剤、ナノテクノロジーの導入、ライフサイクル管理と再製剤戦略が含まれます。

慢性疾患の増加は、医薬品製剤市場の拡大を牽引すると予想されます。慢性疾患は1年またはそれ以上続くため、継続的な治療が必要となり、日常生活が制限されることが多くあります。医薬品製剤は、慢性疾患の蔓延を緩和する潜在的なソリューションであり、副作用を最小限に抑えながら治療効果を最適化するために複数のドラッグデリバリー方法を採用しています。2022年9月に米国国立衛生研究所（NIH）が発表した報告書によると、米国では50歳以上で少なくとも1つの慢性疾患を持つ人の数が99.5％増加し、2020年の7,152万人から2050年には1億4,266万人になると推定されています。さらに、多疾患併存者の数は、2020年の783万400人から2050年には1,496万8,000人へと91.16％増加すると予測されています。したがって、慢性疾患の有病率の増加が医薬品製剤市場の拡大を促進しています。

個別化医療の採用拡大が医薬品製剤市場の成長を後押すると予想されます。個別化医療は、個々の患者の特性に基づいて治療や介入を調整する革新的なヘルスケアアプローチです。このアプローチでは、遺伝学やバイオマーカーなどの個々の特徴を考慮し、患者ごとに有効性と安全性を最適化するために薬剤の製剤をカスタマイズする必要があります。その影響には、オーダーメイドの治療計画、ゲノムの知見を統合した製剤、薬剤反応の向上、希少疾患の個別化治療などが含まれます。例えば、2022年のPersonalized Medicine Coalition（PMC）によると、食品医薬品局（Food and Drug Administration）の医薬品評価研究センター（CDER）は37の新規分子実体（NME）を承認し、そのうち約34％（12品目）はPMCによって個別化医薬品に分類されました。このように、個別化医療の採用拡大が医薬品製剤市場の成長促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の医薬品製剤市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の医薬品製剤市場：成長率分析
• 世界の医薬品製剤市場の実績：規模と成長、2019～2024年
• 世界の医薬品製剤市場の予測：規模と成長、2024～2029年、2034年
• 世界の医薬品製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の医薬品製剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口製剤
• 非経口製剤
• 局所用製剤
• 吸入製剤
• 世界の医薬品製剤市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• カプセル
• 注射
• スプレー
• 懸濁液
• 粉末
• その他
• 世界の医薬品製剤市場：治療領域別、実績と予測、2019～2024年、2024～2029年、2034年
• 心血管疾患（CVD）
• 疼痛
• 糖尿病
• がん
• 呼吸器疾患
• その他
• 世界の医薬品製剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 大手製薬会社
• 中小製薬
• バイオテクノロジー企業
• 世界の医薬品製剤市場：経口製剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• カプセル
• 粉末
• 液体・溶液
• 世界の医薬品製剤市場：非経口製剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射剤
• インプラント
• 点滴
• 世界の医薬品製剤市場：局所製剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• クリーム
• 軟膏
• ジェル
• 経皮パッチ
• 世界の医薬品製剤市場：吸入製剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 定量噴霧式吸入器（MDI）
• ドライパウダー吸入器（DPI）
• ネブライザー

第7章 地域別・国別分析

• 世界の医薬品製剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の医薬品製剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 医薬品製剤市場：競合情勢
• 医薬品製剤市場：企業プロファイル
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• C.H. Boehringer Sohn AG & Co. KG
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Novo Nordisk A/S
• Amgen Inc.
• Viatris Inc.
• Sandoz International GmbH
• Takeda Pharmaceutical Company Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 医薬品製剤市場2029年：新たな機会を提供する国
• 医薬品製剤市場2029年：新たな機会を提供するセグメント
• 医薬品製剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Drug formulation refers to the process of combining various chemical and biological ingredients, including the active medicine, to produce a finalized pharmaceutical product. This process is crucial for modifying and optimizing drugs during the preclinical stage and initial research.

The primary types of dosage forms for drug formulations include oral formulations, parenteral formulations, topical formulations, and inhalation formulations. Oral formulations involve the development and manufacturing of pharmaceuticals intended for oral delivery. They come in various forms such as tablets, capsules, injectables, sprays, suspensions, powders, and others. These formulations are utilized in treating various conditions such as cardiovascular diseases (CVDs), pain, diabetes, cancer, respiratory diseases, among others. End-users of these formulations include big pharmaceutical companies, small and medium enterprises, as well as biotech companies.

The drug formulation market research report is one of a series of new reports from The Business Research Company that provides drug formulation market statistics, including drug formulation industry global market size, regional shares, competitors with a drug formulation market share, detailed drug formulation market segments, market trends and opportunities, and any further data you may need to thrive in the drug formulation industry. This drug formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug formulation market size has grown strongly in recent years. It will grow from $1908.89 billion in 2024 to $2064.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to biopharmaceutical innovation, patient-centric drug development, personalized medicine, regulatory support for orphan drugs, increased R&D investment.

The drug formulation market size is expected to see strong growth in the next few years. It will grow to $2948.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in 3d printing, focus on pediatric formulations, biological drug delivery systems, green chemistry in formulation, integration of artificial intelligence (ai). Major trends in the forecast period include biopharmaceuticals and biologics dominance, advanced drug delivery systems, personalized medicine and individualized formulations, incorporation of nanotechnology, lifecycle management and reformulation strategies.

The increasing prevalence of chronic diseases is anticipated to drive the expansion of the drug formulation market. Chronic diseases persist for a year or longer, demanding continual medical attention and often restricting daily activities. Drug formulation stands as a potential solution to alleviate the prevalence of chronic ailments, employing multiple drug delivery methods to optimize therapeutic effectiveness while minimizing adverse effects. As per a report from the National Institutes of Health (NIH) in September 2022, the United States expects a 99.5% increase in the number of individuals aged 50 and older with at least one chronic illness, rising from 71.52 million in 2020 to an estimated 142.66 million by 2050. Moreover, the count of individuals with multimorbidity is projected to rise by 91.16%, from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the growing prevalence of chronic diseases fuels the expansion of the drug formulation market.

The escalating adoption of personalized medicine is poised to drive the growth of the drug formulation market. Personalized medicine represents an innovative healthcare approach tailoring medical treatments and interventions based on individual patient characteristics. This approach necessitates customized drug formulations to optimize efficacy and safety for each patient, considering individual traits such as genetics and biomarkers. The impact includes tailored treatment plans, formulations integrating genomic insights, enhanced drug responses, and personalized therapies for rare diseases. For instance, according to the Personalized Medicine Coalition in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the increasing adoption of personalized medicine is a key driver of growth in the drug formulation market.

Technological advancements emerge as a prominent trend fueling the drug formulation market. Key industry players are directing their focus toward introducing innovative technologies to fortify their market positions. For instance, in June 2022, Merck & Co., Inc., a US-based pharmaceutical company, unveiled the Merck Digital Sciences Studio (MDSS), aiming to develop innovative technologies for drug research and development. Leveraging Azure Cloud's robust computing and Merck's expertise, MDSS collaboratively accelerates the creation of novel digital technologies. The initiative, a collaboration between Merck and the New Jersey Innovation Institute (NJII), has secured investments from the Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures. Microsoft will extend technological support to startup companies involved in the initiative.

Leading companies in the drug formulation market are focusing on the development of new fixed-dose combination drugs for type 2 diabetes to enhance their competitive advantage. A Fixed Dose Combination (FDC) refers to a pharmaceutical formulation that includes two or more active ingredients combined in a specific ratio within a single dosage form. For example, in October 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical firm, launched the first triple-drug fixed-dose combination under the brand name Zita DM. This formulation contains the DPP4 inhibitor Teneligliptin (20 mg), the SGLT2 inhibitor Dapagliflozin (10 mg), and Metformin SR (500 mg/1000 mg) in a fixed dose. It is prescribed to be taken once daily to enhance glycemic control in patients with type 2 diabetes.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology firm, acquired Biohaven Pharmaceutical Holding Company Ltd. in a deal valued at $11.6 billion. This acquisition adds a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists to Pfizer's offerings. It enhances the potential to provide new treatment options for patients suffering from migraines, a condition that affects over 1 billion people worldwide. Biohaven Pharmaceutical Holding Company Ltd. is a US-based organization dedicated to the discovery, development, and commercialization of transformative treatments and medications in key therapeutic areas.

Major companies operating in the drug formulation market include AstraZeneca PLC, The Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., C.H. Boehringer Sohn AG & Co. KG, F. Hoffmann-La Roche AG, Johnson & Johnson, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Viatris Inc., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Torrent Pharmaceuticals Limited, Jubilant Life Sciences Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Hikma Pharmaceuticals plc

North America was the largest region in the drug formulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the drug formulation market report during the forecast period. The regions covered in the drug formulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drug formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug formulation market includes revenues earned by entities by providing formulation optimization, process optimization, and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Formulation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug formulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drug formulation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Dosage Form: Oral formulations; Parenteral Formulations; Topical Formulations; Inhalation Formulations
• 2) By Formulation: Tablets; Capsules; Injectable; Sprays; Suspensions; Powders; Other Formulations
• 3) By Therapy Area: Cardiovascular Diseases (CVDs); Pain; Diabetes; Cancer; Respiratory Diseases; Other Diseases
• 4) By End-User: Big Pharma; Small And Medium Pharma; Biotech Companies
• Subsegments:
• 1) By Oral Formulations: Tablets; Capsules; Powders; Liquids Or Solutions
• 2) By Parenteral Formulations: Injectables; Implants; Infusions
• 3) By Topical Formulations: Creams; Ointments; Gels; Transdermal Patches
• 4) By Inhalation Formulations: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers
• Companies Mentioned: AstraZeneca PLC; The Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drug Formulation Market Characteristics

3. Drug Formulation Market Trends And Strategies

4. Drug Formulation Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Drug Formulation Growth Analysis And Strategic Analysis Framework

• 5.1. Global Drug Formulation PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Drug Formulation Market Growth Rate Analysis
• 5.4. Global Drug Formulation Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Drug Formulation Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Drug Formulation Total Addressable Market (TAM)

6. Drug Formulation Market Segmentation

• 6.1. Global Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral formulations
• Parenteral Formulations
• Topical Formulations
• Inhalation Formulations
• 6.2. Global Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
• 6.3. Global Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Diseases (CVDs)
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Other Diseases
• 6.4. Global Drug Formulation Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Big Pharma
• Small And Medium Pharma
• Biotech Companies
• 6.5. Global Drug Formulation Market, Sub-Segmentation Of Oral Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Powders
• Liquids Or Solutions
• 6.6. Global Drug Formulation Market, Sub-Segmentation Of Parenteral Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Implants
• Infusions
• 6.7. Global Drug Formulation Market, Sub-Segmentation Of Topical Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creams
• Ointments
• Gels
• Transdermal Patches
• 6.8. Global Drug Formulation Market, Sub-Segmentation Of Inhalation Formulations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metered-Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Nebulizers

7. Drug Formulation Market Regional And Country Analysis

• 7.1. Global Drug Formulation Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Drug Formulation Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drug Formulation Market

• 8.1. Asia-Pacific Drug Formulation Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drug Formulation Market

• 9.1. China Drug Formulation Market Overview
• 9.2. China Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drug Formulation Market

• 10.1. India Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drug Formulation Market

• 11.1. Japan Drug Formulation Market Overview
• 11.2. Japan Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drug Formulation Market

• 12.1. Australia Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drug Formulation Market

• 13.1. Indonesia Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drug Formulation Market

• 14.1. South Korea Drug Formulation Market Overview
• 14.2. South Korea Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drug Formulation Market

• 15.1. Western Europe Drug Formulation Market Overview
• 15.2. Western Europe Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drug Formulation Market

• 16.1. UK Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drug Formulation Market

• 17.1. Germany Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drug Formulation Market

• 18.1. France Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drug Formulation Market

• 19.1. Italy Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drug Formulation Market

• 20.1. Spain Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drug Formulation Market

• 21.1. Eastern Europe Drug Formulation Market Overview
• 21.2. Eastern Europe Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drug Formulation Market

• 22.1. Russia Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drug Formulation Market

• 23.1. North America Drug Formulation Market Overview
• 23.2. North America Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drug Formulation Market

• 24.1. USA Drug Formulation Market Overview
• 24.2. USA Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drug Formulation Market

• 25.1. Canada Drug Formulation Market Overview
• 25.2. Canada Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drug Formulation Market

• 26.1. South America Drug Formulation Market Overview
• 26.2. South America Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drug Formulation Market

• 27.1. Brazil Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drug Formulation Market

• 28.1. Middle East Drug Formulation Market Overview
• 28.2. Middle East Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drug Formulation Market

• 29.1. Africa Drug Formulation Market Overview
• 29.2. Africa Drug Formulation Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Drug Formulation Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Drug Formulation Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drug Formulation Market Competitive Landscape And Company Profiles

• 30.1. Drug Formulation Market Competitive Landscape
• 30.2. Drug Formulation Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Drug Formulation Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Pfizer Inc.
• 31.3. AbbVie Inc.
• 31.4. C.H. Boehringer Sohn AG & Co. KG
• 31.5. F. Hoffmann-La Roche AG
• 31.6. Johnson & Johnson
• 31.7. Bayer AG
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Sanofi S.A.
• 31.10. GlaxoSmithKline plc
• 31.11. Novo Nordisk A/S
• 31.12. Amgen Inc.
• 31.13. Viatris Inc.
• 31.14. Sandoz International GmbH
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Drug Formulation Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Formulation Market

34. Recent Developments In The Drug Formulation Market

35. Drug Formulation Market High Potential Countries, Segments and Strategies

• 35.1 Drug Formulation Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Drug Formulation Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Drug Formulation Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer